Marvel Biosciences Corp (V:MRVL) — Market Cap & Net Worth
Market Cap & Net Worth: Marvel Biosciences Corp (MRVL)
Marvel Biosciences Corp (V:MRVL) has a market capitalization of $7.13 Million (CA$9.86 Million) as of April 21, 2026. Listed on the V stock exchange, this Canada-based company holds position #31272 globally and #1243 in its home market, demonstrating a 25.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Marvel Biosciences Corp's stock price CA$0.17 by its total outstanding shares 58004481 (58.00 Million).
Marvel Biosciences Corp Market Cap History: 2021 to 2026
Marvel Biosciences Corp's market capitalization history from 2021 to 2026. Data shows change from $11.33 Million to $7.13 Million (-15.99% CAGR).
Marvel Biosciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Marvel Biosciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MRVL by Market Capitalization
Companies near Marvel Biosciences Corp in the global market cap rankings as of April 21, 2026.
Key companies related to Marvel Biosciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #298 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #455 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #456 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #298 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #455 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #456 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
Marvel Biosciences Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Marvel Biosciences Corp's market cap moved from $11.33 Million to $ 7.13 Million, with a yearly change of -15.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$7.13 Million | +25.93% |
| 2025 | CA$5.66 Million | -20.59% |
| 2024 | CA$7.13 Million | +112.50% |
| 2023 | CA$3.36 Million | -36.00% |
| 2022 | CA$5.24 Million | -53.70% |
| 2021 | CA$11.33 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 20th, 2026 the market cap of Marvel Biosciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.13 Million USD |
| MoneyControl | $7.13 Million USD |
| MarketWatch | $7.13 Million USD |
| marketcap.company | $7.13 Million USD |
| Reuters | $7.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more